according to Pfizer. Administering a third dose restores protective efficacy back up to 95% or more, it said. Meanwhile, Moderna also reported new data with its mRNA-1273 jab – which won't be ...

Pfizer (PFE) announced that the U.S. FDA has approved the supplemental Biologics License Application for ADCETRIS in combination with ...

1 lineage of Omicron but is already being superseded by sister strain KP.3. Still, Pfizer/BioNTech and Moderna say they expect their new vaccines will retain protective efficacy as the two strains ...

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for ADCETRIS® (brentuximab vedotin) in combination with ...

NEW YORK - Pfizer Inc. (NYSE: NYSE:PFE), a pharmaceutical giant with a market capitalization of $150 billion and annual revenue exceeding $59 billion, announced today that its Phase 3 BREAKWATER study ...

Bourla and Afeyan said they began talking about this new approach in the depths of the pandemic, when they were “partners-slash-competitors,” as Bourla puts it, in the effort to create a vaccine.

the technology used in the Moderna and Pfizer shots, the researchers said. In clinical trials, J&J's vaccine had shown an 85% efficacy. In subsequent studies in the general population, this figure ...

But Truist analysts Asthika Goonewardene and Karina Rabayeva said that they believe the declining outlook on COVID-19 vaccination rates in 2025 may be restricted to just Moderna’s vaccine, perhaps ...

The stellar efficacy and safety profile of ... by other innovative vaccines (GSK's Shingrix, Pfizer's Prevnar) launched in recent years. Moderna's platform technology allows new genetic sequences ...